June 23, 2025 Sophia Vida
Breaking News

BioStem Technologies Completes Enrollment in Clinical Trial Evaluating BioREtain® Amnion Chorion for Treatment of Diabetic Foot Ulcers

Head-to-head study comparing BioREtain®– processed Amnion Chorion (BR-AC) allograft to standard of care initiated in Q4 2024 to demonstrate healing superiority Topline results and full data analysis expected in Q4 2025 Audio Overview – Listened: POMPANO BEACH, Fla., June 23, 2025 – PRISM MediaWire – BioStem Technologies, Inc. (“BioStem” or the “Company”) (OTC: BSEM), a … Continue reading “BioStem Technologies Completes Enrollment in Clinical Trial Evaluating BioREtain® Amnion Chorion for Treatment of Diabetic Foot Ulcers”